ArticleProceedings of the National Academy of Sciences of the United States of America1995
Inflammation-induced recombinant protein expression in vivo using promoters from acute-phase protein genes.
Article in Proceedings of the National Academy of Sciences of the United States of America, 1995. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 67 citations in OpenAlex.
- Article
- Article
- The role of SOCS3 in the hypothalamic paraventricular nucleus in rat model of inflammatory pain.Journal of inflammation (London, England) · 2020Article
- Article
- Assembly PCR synthesis of optimally designed, compact, multi-responsive promoters suited to gene therapy application.Scientific reports · 2016Article
- Immunomodulatory effect of chinese herbal medicine formula sheng-fei-yu-chuan-tang in lipopolysaccharide-induced acute lung injury mice.Evidence-based complementary and alternative medicine : eCAM · 2013Article
- Adenoviral targeting of gene expression to tumors.Cancer gene therapy · 2010Article
- Computational design and application of endogenous promoters for transcriptionally targeted gene therapy for rheumatoid arthritis.Molecular therapy : the journal of the American Society of Gene Therapy · 2009Article
- Application of a disease-regulated promoter is a safer mode of local IL-4 gene therapy for arthritis.Gene therapy · 2007Article
- Gene therapy works in animal models of rheumatoid arthritis...so what!Current rheumatology reports · 2006Review
- Analysis of signal transduction pathways in macrophages using expression vectors with CMV promoters: a cautionary tale.Inflammation · 2005Article
- Gene therapy in animal models of rheumatoid arthritis: are we ready for the patients?Arthritis research & therapy · 2004Review
- Endogenous regulation of a therapeutic transgene restores homeostasis in arthritic joints.The Journal of clinical investigation · 2002Article
- Induction of the cytokine signal regulator SOCS3/CIS3 as a therapeutic strategy for treating inflammatory arthritis.The Journal of clinical investigation · 2001Article
- Creation of an In vivo cytosensor using engineered mesangial cells. Automatic sensing of glomerular inflammation controls transgene activity.The Journal of clinical investigation · 1997Article
- Long-term gene delivery into the livers of immunocompetent mice with E1/E4-defective adenoviruses.Journal of virology · 1997Article
- Adenoviral-mediated delivery of herpes simplex virus thymidine kinase results in tumor reduction and prolonged survival in a SCID mouse model of human ovarian carcinoma.Journal of molecular medicine (Berlin, Germany) · 1996Article
- Adenovirus-mediated transfer of a gene encoding acyloxyacyl hydrolase (AOAH) into mice increases tissue and plasma AOAH activity.Infection and immunity · 1996Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
Abstract
We report that promoters for two murine acute-phase protein (APP) genes, complement factor 3 (C3) and serum amyloid A3 (SAA3), can increase recombinant protein expression in response to inflammatory stimuli in vivo. To deliver APP promoter-luciferase reporter gene constructs to the liver, where most endogenous APP synthesis occurs, we introduced them into a nonreplicating adenovirus vector and injected the purified viruses intravenously into mice. When compared with the low levels of basal luciferase expression observed prior to inflammatory challenge, markedly increased expression from the C3 promoter was detected in liver in response to both lipopolysaccharide (LPS) and turpentine, and lower-level inducible expression was also found in lung. In contrast, expression from the SAA3 promoter was found only in liver and was much more responsive to LPS than to turpentine. After LPS challenge, hepatic luciferase expression increased rapidly and in proportion to the LPS dose. Use of cytokine-inducible promoters in gene transfer vectors may make it possible to produce antiinflammatory proteins in vivo in direct relationship to the intensity and duration of an individual's inflammatory response. By providing endogenously controlled production of recombinant antiinflammatory proteins, this approach might limit the severity of the inflammatory response without interfering with the beneficial components of host defense and immunity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.